Home
 Home | Univ of Michigan | College of Pharmacy | Medicinal Chemistry | About Us

Selected Publications
Selected Publication Information ID#
Lomize A.L., Pogozheva I.D.
TMDOCK: An energy-based method for modeling α-helical dimers in membranes.
J Mol Biol, 429: pii: S0022-2836(16)30369-2 [Epub] (2017)
113
Lomize A.L., Lomize M.A., Krolicki S.R., Pogozheva I.D.
Membranome: a database for proteome-wide analysis of single-pass membrane proteins.
Nucleic Acids Res, 45(D1): pii: gkw712 [Epub] (2017)
112
Anand J.P., Boyer B.T., Mosberg H.I., Jutkiewicz E.M.
The behavioral effects of a mixed efficacy antinociceptive peptide, VRP26, following chronic administration in mice
Psychopharmacology (Berl), 233: 2479-2487 (2016)
111
Harland A.A., Bender A.M., Griggs N.W., Gao C., Anand J.P., Pogozheva I.D., Traynor J.R., Jutkiewicz E.M., Mosberg H.I.
Effects of N-substitutions on the tetrahydroquinoline (THQ) core of mixed-efficacy mu-opioid receptor (MOR)/delta-opioid receptor (DOR) ligands
J Med Chem, 59: 4985-4998 (2016)
110
Geng J., Pogozheva I.D., Mosberg H.I., Raghavan M.
Use of functional polymorphisms to elucidate the peptide binding site of TAP complexes
J Immunol, 196: pii: 1500985 (2015)
106
Antonenko Y.N., Gluhov G.S., Firsov A.M., Pogozheva I.D., Kovalchuk S.I., Pechnikova E.V., Kotova E.A., Sokolova O.S.
Gramicidin A disassembles large conductive clusters of its lysine-substituted derivatives in lipid membranes
Phys Chem Chem Phys, 17: 17461-17470 (2015)
107
Harland A.A., Yeomans L., Griggs N.W., Anand J.P., Pogozheva I.D., Jutkiewicz E.M., Traynor J.R., Mosberg H.I.
Further optimization and evaluation of bioavailable, mixed-efficacy mu-opioid receptor (MOR) agonists/delta-opioid receptor (DOR) antagonists: balancing MOR and DOR affinities
J Med Chem, 58: 8952-8969 (2015)
109
Bender A.M., Clark M.J., Agius M.P., Traynor J.R., Mosberg H.I.
Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity mu opioid receptor (MOR) agonist/delta opioid receptor (DOR) antagonist ligands
Bioorg Med Chem Lett, 24: 548-551 (2014)
97
Ding B., Glukhova A., Sobczyk-Kojiro K., Mosberg H.I., Tesmer J.J., Chen Z.
Unveiling the membrane-binding properties of N-terminal and C-terminal regions of G protein-coupled receptor kinase 5 by combined optical spectroscopies
Langmuir, 30: 823-831 (2014)
98
Anand J.P., Porter-Barrus V.R., Waldschmidt H.V., Yeomans L., Pogozheva I.D., Traynor J.R., Mosberg H.I.
Translation of structure-activity relationships from cyclic mixed efficacy opioid peptides to linear analogues
Biopolymers, 102: 107-114 (2014)
99
Mosberg H.I., Yeomans L., Anand J.P., Porter V., Sobczyk-Kojiro K., Traynor J.R., Jutkiewicz E.M.
Development of a bioavailable mu opioid receptor (MOPr) agonist, delta opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance
J Med Chem, 57: 3148-3153 (2014)
100
Bender A.M., Griggs N.W., Anand J.P., Traynor J.R., Jutkiewicz E.M., Mosberg H.I.
Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy mu opioid receptor/delta opioid receptor ligands
ACS Chem Neurosci, 6: 1428-1435 (2014)
102
Kumar V., Ridzwan I.E., Grivas K., Lewis J.W., Clark M.J., Meurice C., Jimenez-Gomez C., Pogozheva I., Mosberg H., Traynor J.R., Husbands S.M.
Selectively promiscuous opioid ligands: discovery of high affinity/low efficacy opioid ligands with substantial nociceptin opioid peptide receptor affinity
J Med Chem, 57: 4049-4057 (2014)
104
Pogozheva I.D., Mosberg H.I., Lomize A.L.
Life at the border: adaptation of proteins to anisotropic membrane environment
Protein Sci, 23: 1165-1196 (2014)
101
Mosberg H.I., Yeomans L., Harland A.A., Bender A.M., Sobczyk-Kojiro K., Anand J.P., Clark M.J., Jutkiewicz E.M., Traynor J.R.
Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy mu opioid receptor (MOR) agonist/delta opioid receptor (DOR) antagonist ligands
J Med Chem, 56: 2139-2149 (2013)
94
Madhongsa K., Pasan S., Phophetleb O., Nasompag S., Thammasirirak S., Daduang S., Taweechaisupapong S., Lomize A.L., Patramanon R.
Antimicrobial action of the cyclic peptide bactenecin on Burkholderia pseudomallei correlates with efficient membrane permeabilization
PLoS Negl Trop Dis, 7: e2267 (2013)
105
Pogozheva I.D., Tristram-Nagle S., Mosberg H.I., Lomize A.L.
Structural adaptations of proteins to different biological membranes
Biochim Biophys Acta-Biomembranes, 1828: 2592-2608 (2013)
96
Lomize A.L., Pogozheva I.D.
Solvation models and computational prediction of orientations of peptides and proteins in membranes
Methods Mol Biol, 1063: 125-142 (2013)
95
Anand J.P., Purington L.C., Pogozheva I.D., Traynor J.R., Mosberg H.I.
Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models
Chem Biol Drug Des, 80: 763-770 (2012)
93
Janovick J.A., Pogozheva I.D., Mosberg H.I., Cornea A., Conn P.M.
Rescue of misrouted GnRHR Mutants reveals its constitutive activity
Mol Endocrinol, 26: 1179-1188 (2012)
92
Lomize M.A., Pogozheva I.D., Joo H., Mosberg H.I., Lomize A.L.
OPM database and PPM web server: resources for positioning of proteins in membranes
Nucleic Acids Res, 40(Database issue): D370-D376 (2012)
89
Purington L.C., Sobczyk-Kojiro K., Pogozheva I.D., Traynor J.R., Mosberg H.I.
Development and in vitro characterization of a novel bifunctional mu-agonist/delta-antagonist opioid tetrapeptide
ACS Chem Biol, 6: 1375-1381 (2011)
91
Lomize AL, Pogozheva ID, Mosberg HI.
Anisotropic solvent model of the lipid bilayer. 1. Parameterization of long-range electrostatics and first solvation shell effects.
J Chem Inf Model, 51: 918-929 (2011)
79
Lomize AL, Pogozheva ID, Mosberg HI.
Anisotropic solvent model of the lipid bilayer. 2. Energetics of insertion of small molecules, peptides, and proteins in membranes.
J Chem Inf Model, 51: 930-946 (2011)
80
Janovick JA, Pogozheva ID, Mosberg HI, Conn PM.
Salt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for g protein-coupled receptor activation.
J Pharmacol Exp Ther, 338: 430-442 (2011)
81
Zhang WX, Thakur V, Lomize A, Pogozheva I, Panagabko C, Cecchini M, Baptist M, Morley S, Manor D, Atkinson J.
The contribution of surface residues to membrane binding and ligand transfer by the α-tocopherol transfer protein (α-TTP).
J Mol Biol, 405: 972-988 (2011)
82
Burman R, Herrmann A, Tran R, Kivelä JE, Lomize A, Gullbo J, Göransson U.
Cytotoxic potency of small macrocyclic knot proteins: structure-activity and mechanistic studies of native and chemically modified cyclotides.
Org Biomol Chem, 9: 4306-4314 (2011)
84
Ho D, Lugo MR, Lomize AL, Pogozheva ID, Singh SP, Schwan AL, Merrill AR.
Membrane topology of the colicin E1 channel using genetically encoded fluorescence.
Biochemistry, 50: 4830-4842 (2011)
86
Girnys E.A., Porter V.R., Mosberg H.I.
Conformationally restricted analogs of the direct thrombin inhibitor FM 19
Bioorg Med Chem, 19: 7425-7434 (2011)
88
Kumar A., Lomize A., Jin K.K., Carlton D., Miller M.D., Jaroszewski L., Abdubek P., Astakhova T., Axelrod H. L., Chiu H.-J., Clayton T., Das D., et al
Open and closed conformations of two SpoIIAA-like proteins (YP_749275.1 and YP_001095227.1) provide insights into membrane association and ligand binding.
Acta Crystallogr, F66: doi: 10.1107/S1744309109042481 (2010)
69
Chi H.-J., Bakolitsa C., Skerra A., Lomize A., Carlton D., Miller M.D., Krishna S.S., Abdubek P., Astakhova T., Axelrod H. L., Clayton T., et al.,
Structure of the first representative of Pfam familyPF09410 (DUF2006) reveals a structural signature of the calycin superfamily that suggests a role in lipid metabolism.
Acta Crystallogr, F 66: doi:10.1107/S1744309109037749 (2010)
73
Girnys EA, Sobczyk-Kojiro K, Mosberg HI.
Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19.
Chem Biol Drug Des, 75(1): 35-39 (2010)
74
René P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, Valenzano KJ, Bouvier M.
Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity.
J Pharmacol Exp Ther, 335: 520-532 (2010)
78
Tan K, Pogozheva ID, Yeo GS, Hadaschik D, Keogh JM, Haskell-Leuvano C, O Rahilly S, Mosberg HI, Farooqi IS.
Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor.
Endocrinology, 150(1): 114-125 (2009)
76
Haskell-Luevano C, Xiang Z, Wilczynski AM, Haskell KR, Andreasen AM, Litherland SA, Millard WJ, Pogozheva ID, Mosberg HI, Sorenson NB.
Discovery of a ligand that compensates for decreased endogenous agonist potency of melanocortin-4 receptor polymorphisms identified in obese humans.
Adv Exp Med Biol, 611: 509-510 (2009)
62
Roof RA, Roman DL, Clements ST, Sobczyk-Kojiro K, Blazer LL, Ota S, Mosberg HI, Neubig RR.
A covalent peptide inhibitor of RGS4 identified in a focused one-bead, one compound library screen.
BMC Pharmacol., 9: 9 (2009)
63
Purington LC, Pogozheva ID, Traynor JR, Mosberg HI.
Pentapeptides displaying mu opioid receptor agonist and delta opioid receptor partial agonist/antagonist properties.
J Med Chem, 52(23): 7724-7731 (2009)
67
Kuszak AJ, Pitchiaya S, Anand JP, Mosberg HI, Walter NG, Sunahara RK.
Purification and functional reconstitution of monomeric mu-opioid receptors: allosteric modulation of agonist binding by Gi2.
J Biol Chem, 284(39): 26732-26741 (2009)
65
Roof RA, Sobczyk-Kojiro K, Turbiak AJ, Roman DL, Pogozheva ID, Blazer LL, Neubig RR, Mosberg HI.
Novel peptide ligands of RGS4 from a focused one-bead, one-compound library.
Chem Biol Drug Des, 72(2): 111-119 (2008)
59
Proneth B, Pogozheva ID, Portillo FP, Mosberg HI, Haskell-Luevano C.
Melanocortin tetrapeptide Ac-His-DPhe-Arg-Trp-NH2 modified at the para position of the benzyl side chain (DPhe): importance for mouse melanocortin-3 receptor agonist versus antagonist activity.
J Med Chem, 51(18): 5585-5593 (2008)
57
Nieman MT, Burke F, Warnock M, Zhou Y, Sweigart J, Chen A, Ricketts D, Lucchesi BR, Chen Z, Di Cera E, Hilfinger J, Kim JS, Mosberg HI, Schmaier AH.
Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo
J Thromb Haemost, 6(5): 837-845 (2008)
56
Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI
The role of hydrophobic interactions in positioning of peripheral proteins in membranes
BMC Struct Biol, 7: 44 (2007)
55
Xiang Z, Pogozheva ID, Sorenson NB, Wilczynski AM, Holder JR, Litherland SA, Millard WJ, Mosberg HI, Haskell-Luevano C.
Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms
Biochemistry, 46(28): 8273-8287 (2007)
54
Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI
OPM: orientations of proteins in membranes database.
Bioinformatics, 22: 623-625 (2006)
53
Proneth B, Xiang Z, Pogozheva ID, Litherland SA, Gorbatyuk OS, Shaw AM, Millard WJ, Mosberg HI, Haskell-Luevano C
Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism
Chem. Biol. Drug. Des., 67: 215-229 (2006)
52
Lomize AL, Pogozheva ID, Lomize MA, Mosberg HI
Positioning of proteins in membranes: a computational approach
Protein Sci., 15: 1318-1333 (2006)
51
Burke FM, Warnock M, Schmaier AH, Mosberg HI
Synthesis of novel peptide inhibitors of thrombin-induced platelet activation
Chem. Biol. Drug. Des., 68: 235-258 (2006)
50
Roof RA, Jin Y, Roman DL, Sunahara RK, Ishii M, Mosberg HI, Neubig RR
Mechanism of Action and Structural Requirements of Constrained Peptide Inhibitors of RGS Proteins
Chem. Biol. Drug. Des., 67: 266-274 (2006)
45
Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH
Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.
Brain Res., 1069: 172-181 (2006)
44
Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K, Mosberg HI, Folk JE, Rice KC, Watson SJ, Woods JH
Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects.
Eur J Pharmacol., 531: 151-159 (2006)
43
Chai B-X, Pogozheva ID, Lai Y-M, Li J-Y, Neubig RR, Mosberg HI, Gantz I
Receptor-antagonist interactions in the complexes of agouti protein and agouti-related protein with human melanocortin 1 and 4 receptors.
Biochemistry, 44: 3418-3431 (2005)
36
Przydzial MJ, Pogozheva ID, Bosse KE, Andrews SM, Tod A, Tharp TA, Traynor JR, Mosberg HI
Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa- opioid receptor
J. Pept. Res., 65: 333-342 (2005)
38
Pogozheva ID, Chai B-X, Lomize AL, Fong TM, Weinberg DH, Nargund RH, Mulholland MW, Gantz I, Mosberg HI
Interactions of human melanocortin receptor-4 with small-molecule agonists.
Biochemistry, 44: 11329-11341 (2005)
37
Przydzial MJ, Pogozheva ID, Ho JC, Tharp TA, Drankhan KE, Sawyer E, Traynor JR, Mosberg HI
Design of high affinity cyclic pentapeptide ligands for kappa-opioid receptors.
J. Pept. Res., 66: 255-262 (2005)
39
Pogozheva ID, Przydzial MJ, Mosberg HI
Homology modeling of opioid receptor-ligand complexes using experimental constraints.
AAPS J., 7: E434-E448 (2005)
40
Kneen MM, Pogozheva ID, Kenyon GL, McLeish MJ
Exploring the active site of benzaldehyde lyase by modeling and mutagenesis
Biochim. Biophys. Acta, 1753: 263-271 (2005)
41
Jameson EE, Roof RA, Whorton MR, Mosberg HI, Sunahara RK, Neubig RR Kennedy RT
Real-time detection of basal and stimulated G protein GTPase activity using fluorescent GTP analogues.
J Biol Chem., 280: 7712-7719 (2005)
42
Fowler CB, Pogozheva ID, LeVine H 3rd, Mosberg HI.
Refinement of a homology model of the mu-opioid receptor using distance constraints from intrinsic and engineered zinc-binding sites.
Biochemistry., 43: 8700-8710 (2004)
28
Jin Y, Zhong H, Omnaas JR, Neubig RR, Mosberg HI
Structure-based design, synthesis, and pharmacologic evaluation of peptide RGS4 inhibitors.
J. Pept. Res., 63: 141-146 (2004)
31
Jin Y, Zhong H, Omnaas JR, Neubig RR, Mosberg HI
Structure-based design, synthesis, and activity of peptide inhibitors of RGS4 GAP activity.
Methods Enzymol., 389: 266-277 (2004)
33
Lomize AL, Pogozheva ID, Mosberg HI
Quantification of helix-helix binding affinities in micelles and lipid bilayers.
Protein Sci., 13: 2600-2612 (2004)
34
Kent UM, Pascual L, Roof RA, Ballou DP, Hollenberg PF
Mechanistic studies with N-benzyl-1-aminobenzotriazole-inactivated CYP2B1: differential effects on the metabolism of 7-ethoxy-4-(trifluoromethyl)coumarin, testosterone, and benzphetamine
Arch Biochem. Biophys., 423: 277-287 (2004)
48
Fowler CB, Pogozheva ID, Lomize AL, LeVine H, Mosberg HI
Complex of active mu-opioid receptor with cyclic peptide agonist modeled from experimental constraints.
Biochemistry, 43: 15796-15810 (2004)
35
Vig BS, Lorenzi PJ, Mittal S, Landowski CP, Shin HC, Mosberg HI, Hilfinger JM, Amidon GL
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis.
Pharm. Res., 20: 1381-1388 (2003)
30
Munshi UM, Pogozheva ID, Menon KM
Highly conserved serine in the third transmembrane helix of the luteinizing hormone/human chorionic gonadotropin receptor regulates receptor activation.
Biochemistry., 42: 3708-3715 (2003)
29
Poulsen A, Bjornholm B, Gundertofte K, Pogozheva ID, Liljefors T
Pharmacophore and receptor models for neurokinin receptors.
J. Comput. Aided. Mol. Des., 17: 765-783 (2003)
32
Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, Woods JH, Naughton NN
Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys.
J. Pharmacol. Exp. Ther., 305: 173-179 (2003)
27
Chung DA, Wade SM, Fowler CB, Woods DD, Abada PB, Mosberg HI, Neubig RR
Mutagenesis and peptide analysis of the DRY motif in the alpha2A adrenergic receptor: evidence for alternate mechanisms in G protein-coupled receptors.
Biochem. Biophys. Res. Commun., 293: 1233-1241 (2002)
2
Chung DA, Zuiderweg ER, Fowler CB, Soyer OS, Mosberg HI, Neubig RR
NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: evidence for a novel cytoplasmic helix.
Biochemistry, 41: 1223-1241 (2002)
3
Lomize AL, Reibarkh MY, Pogozheva ID
Interatomic potentials and solvation parameters from protein engineering data for buried residues.
Protein Sci., 11: 1984-2000 (2002)
5
Hallock KJ, Lee DK, Omnaas J, Mosberg HI, Ramamoorthy A
Membrane composition determines pardaxin's mechanism of lipid bilayer disruption.
Biophys. J., 83: 1004-1013 (2002)
1
Mosberg HI, Fowler CB
Development and validation of opioid ligand-receptor interaction models: The structural basis of mu vs. delta selectivity
J. Peptide Res., 60: 329-332 (2002)
25
Hicks ME, Gomez-Flores R, Wang C, Mosberg HI, Weber RJ
Differential effects of the novel non-peptidic opioid 4-tyrosylamido-6-benzyl-1,2,3,4 tetrahydroquinoline (CGPM-9) on in vitro rat t lymphocyte and macrophage functions.
Life Sci., 68: 2685-2694 (2001)
4
McFadyen IJ, Sobczyk-Kojiro K, Schaefer MJ, Ho JC, Omnaas JR, Mosberg HI, Traynor JR
Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.
Pharmacol. Exp. Ther., 295: 960-966 (2000)
7
McFadyen IJ, Ho JC, Mosberg HI, Traynor JR
Modifications of the cyclic mu receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]NH2 (Et): effects on opioid receptor binding and activation.
J. Pept. Res., 55: 255-261 (2000)
9
Ko MC, Johnson MD, Butelman ER, Willmont KJ, Mosberg HI, Woods JH
Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.
J. Pharmacol. Exp. Ther., 291: 1113-1120 (1999)
19
Lomize AL, Pogozheva ID, Mosberg HI
Prediction of protein structure: The problem of fold multiplicity.
Proteins, 37: 199-203 (1999)
6
Mosberg HI
Complementarity of delta opioid ligand pharmacophore and receptor models.
Biopolymers, 51: 426-39 (1999)
8
Lomize AL, Pogozheva ID, Mosberg HI
Structural organization of G-protein-coupled receptors.
J. Comput. Aided Mol. Des., 13: 325-353 (1999)
10
Johnson MD, Ko M, Choo KS, Traynor JR, Mosberg HI, Naughton NN, Woods JH
The effects of the phyllolitorin analogue [desTrp(3), Leu(8)]phyllolitorin on scratching induced by bombesin and related peptides in rats.
Brain Res., 839: 194-198 (1999)
20
Mosberg HI, Ho JC, Sobczyk-Kojiro K
A high affinity, mu-opioid receptor-selective enkephalin analogue lacking an N-terminal tyrosine.
Bioorg. Med. Chem. Lett., 8: 2681-2684 (1998)
12
Butelman ER, Ko MC, Sobczyk-Kojiro K, Mosberg HI, Van Bemmel B, Zernig G, Woods JH
kappa-Opioid receptor binding populations in rhesus monkey brain: relationship to an assay of thermal antinociception.
J. Pharmacol. Exp. Ther., 285: 595-601 (1998)
21
Pogozheva ID, Lomize AL, Mosberg HI
Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints.
Biophys. J., 75: 612-634 (1998)
13
Wang C, McFadyen IJ, Traynor JR, Mosberg HI
Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models.
Bioorg. Med. Chem. Lett., 8: 2685-2688 (1998)
11
Lomize AL, Mosberg HI
Thermodynamic model of secondary structure for alpha-helical peptides and proteins.
Biopolymers., 42: 239-269 (1997)
14
Pogozheva ID, Lomize AL, Mosberg HI
The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints.
Biophys. J., 72: 1963-1985 (1997)
15
Lomize AL, Pogozheva ID, Mosberg HI
Development of a model for the delta-opioid receptor pharmacophore: 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Pen]OH with other conformationally constrained delta-receptor selective ligands.
Biopolymers., 38: 221-234 (1996)
16
Mosberg HI, Dua RK, Pogozheva ID, Lomize AL
Development of a model for the delta-opioid receptor pharmacophore. 4. Residue 3dehydrophenylalanine analogues of Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13) confirmrequired gauche orientation of aromatic side chain.
Biopolymers, 39: 287-296 (1996)
26
Mosberg HI, Omnaas JR, Lomize AL, Heyl DL, Nordan I, Mousigian C, Davis P, Porreca F
Development of a model for the delta opioid receptor pharmacophore. 2. Conformationally restricted Phe3 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
J. Med. Chem., 37: 4384-4391 (1994)
17
Mosberg HI, Lomize AL, Wang C, Kroona H, Heyl DL, Sobczyk-Kojiro K, Ma W, Mousigian C, Porreca F
Development of a model for the delta opioid receptor pharmacophore. 1. Conformationally restricted Tyr1 replacements in the cyclic delta receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13).
J. Med. Chem., 37: 4371-4383 (1994)
18
People People
Projects Projects
Publications Publications
Resources Resources


 Copyright Mikhail A. Lomize   |   Home   |   About Us   |   Contact Lab   |   Login